# Zentalis Pharmaceuticals, Inc.

**ZNTL**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001725160

# None

**No letter**

5 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $289.0M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | short runway, thin data, degenerate in...<br>not computable: distress, fortress balance sheet |
| **Inputs computable** | 5 of 14 |
| **Graded from** | filings received through Mar 26, 2026<br>231 days before the rescan; latest periodic filing 10-Q received Nov 9, 2026 |
| **Last close** | $1.89<br>2026-11-11; market equity $185.2M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 26, 2026*

We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. We are currently focused on advancing the clinical development of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, or PROC.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 70.1** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Accruals ratio | (3.3%) | (6.6%) | | 70.1 | 801 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 43.2** | | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | | |
| Altman Z double-prime | (8.96) | (0.35) | | 60.1 | 745 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 6.93x | 2.95x | | 26.4 | 827 | 2025-12-31 |
| **Growth and financing, sleeve percentile 45.3** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *four annual observations are required; found 2* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.0% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |
| Asset growth, three years | (18.8%) | 2.2% | | 82.1 | 695 | 2025-12-31 |
| Net share issuance, one year | (1.2%) | 2.5% | | 8.5 | 628 | 2026-03-20 |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 2.2 months |
| Thin data | 5 of 14 grade factors are computable; minimum is 7 |
| Degenerate inputs | latest revenue or assets are at or below the $100,000 validity floor |

## What the price implies

*at the 2026-11-11 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 84.7% | (1.9%) | 86 |
| Distance from 52-week high | (71.4%) | (27.8%) | 11 |
| EBIT to enterprise value | not computable | (1.6%) | |
| Free cash flow yield | (67.4%) | (1.0%) | 9 |
| Book value to price | 1.10 | 0.27 | 89 |
| Sales to price | 0.00 | 0.29 | 0 |
| Composite equity issuance, five years | 87.3% | 20.8% | 74 |
| Relative strength against the sector, log excess return | 0.45 | (0.19) | 86 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | pass |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $24.0M |
| Operating cash flow, four quarters | -$133.8M |
| Months of runway | 2.2 |
| Days since last periodic filing | 3 (10-Q received Nov 9, 2026) |
| Median daily dollar volume, 63 sessions | $2.9M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$137.1M | 2025-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$125.2M | 2025-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 3 | assets | us-gaap:Assets | $289.0M | 2025-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 4 | assets | us-gaap:Assets | $430.3M | 2024-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 5 | current assets | us-gaap:AssetsCurrent | $253.2M | 2025-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $36.6M | 2025-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$1.2B | 2025-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$152.8M | 2025-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 9 | book equity | us-gaap:StockholdersEquity | $216.2M | 2025-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 10 | liabilities | us-gaap:Liabilities | $72.8M | 2025-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 11 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $0 | 2025-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 12 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $67.4M | 2024-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 13 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $0 | 2025-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 14 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$170.9M | 2024-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 15 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $221,000 | 2024-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 16 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$207.8M | 2023-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $583,000 | 2023-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 18 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$163.8M | 2022-12-31 | 2025-03-26 | 10-K | 25-000067 |
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $2.5M | 2022-12-31 | 2025-03-26 | 10-K | 25-000067 |
| 20 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $739,000 | 2025-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 21 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$136.6M | 2025-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 22 | income tax | us-gaap:IncomeTaxExpenseBenefit | $442,000 | 2025-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 23 | current assets | us-gaap:AssetsCurrent | $386.1M | 2024-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 24 | current liabilities | us-gaap:LiabilitiesCurrent | $52.7M | 2024-12-31 | 2026-03-26 | 10-K | 26-000014 |
| 25 | assets | us-gaap:Assets | $551.7M | 2023-12-31 | 2025-03-26 | 10-K | 25-000067 |
| 26 | assets | us-gaap:Assets | $539.3M | 2022-12-31 | 2024-02-27 | 10-K | 24-000080 |
| 27 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 70,931,016 | 2026-03-20 | 2026-03-26 | 10-K | 26-000014 |
| 28 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 71,811,508 | 2025-03-21 | 2025-03-26 | 10-K | 25-000067 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.